Table 3 Summary of Secondary Endpoints during Part II
Naproxen 1000 mg (Part I)/1000 mg (Part II) | Etoricoxib 60 mg (Part I)/60 mg (Part II) | Etoricoxib 60 mg (Part I)/90 mg (Part II) | LS mean difference between etoricoxib 60 mg/90 mg vs. Etoricoxib 60 mg/60 mg; p-Value | Etoricoxib 90 mg (Part I/90 mg (Part II) | |
|---|---|---|---|---|---|
Number of Subjects | n = 74 | n = 175 | n = 178 | n = 70 | |
LS Mean Change from Week 6 in Spinal Pain Intensity Over Weeks 10 and 12 (95 % CI) (Inadequate Responders in Part I) | −12.89 (−16.57, −9.20) | −7.26 (−9.73, −4.80) | −9.97 (−12.42, −7.51) | −2.70 (−4.88, −0.52) | −7.69 (−11.48, −3.90) |
LS Mean Change from Week 6 in PGART Over Weeks 10 and 12 (95 % CI) (Inadequate Responders in Part I) | 0.21 (0.07, 0.35) | 0.13 (0.04, 0.23) | 0.21 (0.12, 0.30) | 0.08 (−0.05, 0.21) | 0.28 (0.13, 0.42) |
Number of Subjects | n = 141 | n = 310 | n = 314 | n = 140 | |
Time-weighted LS Mean Change from Baseline in Spinal Pain Intensity Over 26 Weeks (95 % CI) | −38.26 (−41.70, −34.83) | −35.07 (−37.41, −32.73) | −36.30 (−38.65, −33.96) | −1.70 (−5.79, 2.39) | −36.76 (−40.22, −33.31) |